Research 343: Elucidating Levels and Pathways of Human Exposure in Ireland to Brominated Flame Retardants and Perfluoroalkyl Substances

Authors: Stuart Harrad, Daniel Drage, Mohamed Abdallah, Nina Wemken and Marie Coggins

Summary: Brominated flame retardants (BFRs) and perfluoroalkyl substances (PFASs) have been used extensively in applications such as electrical goods, soft furnishings and building insulation foam. The ELEVATE project generated data to facilitate the assessment of human exposure to these chemicals.

Research 343 thumbnail

Published: 2020

ISBN: 978-1-84095-944-4

Pages: 61

Filesize: 2,776 KB

Format: pdf

Download

Project Highlights

Watch the ELEVATE project highlights video

Identifying Pressures

Brominated flame retardants (BFRs) and perfluoroalkyl substances (PFASs) have been used extensively in applications such as electrical goods, soft furnishings and building insulation foam. Given concerns about their environmental persistence, ability to bioaccumulate and adverse health effects, some BFRs and PFASs are listed under the Stockholm Convention on Persistent Organic Pollutants (POPs), an international treaty designed to eliminate POPs and to which Ireland is a party. Previous studies revealed low levels of BFRs and PFASs in Irish foodstuffs and human milk; however, no data existed for Ireland on concentrations of BFRs and PFASs in indoor air and dust, and of PFASs in drinking water. This project generated these data to facilitate the assessment of human exposure to these chemicals, allowing comparison with guidelines on human exposure developed by the European Food Safety Authority (EFSA), the revised European Union Drinking Water Directive, and limits on concentrations of PFASs in drinking water. The project also measured BFRs and PFASs in Irish human milk to facilitate assessment of the success of actions designed to reduce human exposure since the last measurements in 2011.

Informing Policy

Comparison of the concentrations of BFRs in human milk determined in this study and those determined in a 2011 Irish study suggests that restrictions on penta- and octabromodiphenyl ether products and hexabromocyclododecane have successfully reduced human exposure. Probably because of the more recent restriction on decabromodiphenyl ether, concentrations of this BFR in human milk show no significant decline. Moreover, although decabromodiphenyl ethane (DBDPE) was not detected in human milk in 2011, it was detected in this study. Along with elevated concentrations of DBDPE in indoor air and dust, this implies increased use of DBDPE to replace decabromodiphenyl ether. The Irish population’s exposure to PFASs through non-dietary sources falls below the EFSA’s provisional tolerable weekly intake (TWI). Concentrations of PFASs in Irish human milk do not indicate a health concern for nursing infants based on EFSA breastfeeding exposure scenarios. However, pharmacokinetic modelling of the level of adult exposure to PFASs required to support levels in human milk suggests that overall exposure for some individuals may approach or exceed EFSA’s TWI. Detailed study of dietary exposure to PFASs is therefore recommended.

Developing Solutions

The declines in concentrations of some BFRs in human milk from Irish mothers since the previous equivalent study in 2011 suggest that past policies aimed at reducing the exposure of the Irish population to these BFRs have been successful. Such biomonitoring also reveals that measures taken to restrict the use of decabromodiphenyl ether have not yet reduced exposure in Ireland and also suggests increased exposure to DBDPE, a likely replacement for decabromodiphenyl ether. To facilitate ongoing evaluation of the impact of measures taken to reduce human exposure to such chemicals, biomonitoring of BFRs and PFASs in the Irish population is recommended every 5 years.
In addition to continued monitoring of human milk, which in this study has proven an effective biomonitoring tool, measurements should also be made in blood and urine. This will permit assessment of levels of BFRs and PFASs across a wider range of the population and facilitate monitoring of human exposure to less persistent contaminants through their urinary metabolites.

https://www.epa.ie/media/epa-2020/publications/research/research-343-thumbnail.jpg